Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?